Another possible reason is that tumour hypoxemia resulting from anti–VEGF-A/VEGFR therapy lead to the over-expression of matrix components that bind and sequester VEGF-A, rendering anti-VEGF drugs ineffective [86]. This evidence concerns the gene VEGFA and neoplasm.